

Special Issue

Cancer Induced Organ Dysfunctions (Cachexia)

Message from the Guest Editors

Cancer cachexia is a multifactorial syndrome and is associated with the loss of body weight and organ dysfunctions in cancer patients. It varies from 42% to 80%, depending on the oncological status, and is directly responsible for approximately 30% of deaths in cancer patients. It is a multi-organ and complex syndrome with a largely unknown etiology. Metabolic disorders and inflammation are the hallmarks of cancer cachexia. Several mechanisms and signaling pathways have been reported leading to the development of cachexia; however, a definitive orchestrating mechanism remains elusive. Furthermore, no FDA-approved therapeutic regimen for cancer-induced cachexia (dysfunction) is currently available. This Special Issue is focused on understanding the mechanisms of cancer-induced organ dysfunctions (cachexia) and the therapeutic approach in the field of cachexia, including basic, preclinical and clinical studies, and the application of current technologies for the diagnosis of cachexia.

Guest Editors

Prof. Dr. Sham S. Kakar

Department of Physiology, Department of Biochemistry and Molecular Genetics, Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA

Dr. Sarama Saha

Department of Biochemistry, All India Institute of Medical Science (AIIMS), Rishikesh 174001, Uttarakhand, India

Deadline for manuscript submissions

closed (31 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/212043

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)